- PR Newswire•6 months ago
WuXi Biologics Completes Construction of Asia's Largest Perfusion Biologics Manufacturing Facility Using Disposable Bioreactors
SHANGHAI and WUXI, China, Sept. 22, 2016 /PRNewswire/ -- WuXi Biologics, a leading open-access R&D capability and technology platform company dedicated to biologics and a WuXi AppTec company, announced today the opening of a new commercial-scale cGMP biologics perfusion manufacturing facility in Wuxi city, China. In April 2015 WuXi Biologics announced plans to build a $150 million commercial biologics manufacturing facility in Wuxi city. This added capacity will support WuXi's robust biologics commercial manufacturing pipeline and enable WuXi to maintain its position as the premier biologics manufacturer in China as well as a leader worldwide.
- PR Newswire•11 months ago
SHANGHAI, April 27, 2016 /PRNewswire/ -- LabNetwork, a WuXi AppTec company, held a formal signing ceremony in Shanghai announcing strategic cooperation agreements with 8 top-ranking global chemical providers. With the vision of connecting suppliers and buyers on LabNetwork's global platform for research products, the agreements aim to explore development and speed the time to market of innovative and high quality research compounds.
- Zacks•last year
AstraZeneca (AZN) expands its footprints in China; set to buy respiratory business from Takeda.
Requested symbol wasn't found
NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
|Day's Range||0.00 - 0.00|
|52 Week Range|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||N/A|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|